Nuvalent, Inc. - Class A Common Stock (NUVL)
94.77
-2.29 (-2.36%)
NASDAQ · Last Trade: Mar 22nd, 10:06 AM EDT
Detailed Quote
| Previous Close | 97.06 |
|---|---|
| Open | 97.06 |
| Bid | 38.33 |
| Ask | 115.00 |
| Day's Range | 94.43 - 98.70 |
| 52 Week Range | 55.54 - 113.01 |
| Volume | 951,897 |
| Market Cap | 296.57M |
| PE Ratio (TTM) | -16.20 |
| EPS (TTM) | -5.9 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 539,679 |
Chart
About Nuvalent, Inc. - Class A Common Stock (NUVL)
Nuvalent Inc is a biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company specializes in creating innovative drug candidates that aim to effectively treat specific types of tumors by addressing the underlying genetic mechanisms driving disease progression. By leveraging advanced science and technology, Nuvalent strives to improve treatment options and outcomes for patients with difficult-to-treat cancers, emphasizing precision medicine to enhance the efficacy and safety of oncology treatments. Read More
News & Press Releases

Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.
Via The Motley Fool · March 16, 2026

Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.
Via The Motley Fool · March 13, 2026

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Via The Motley Fool · March 13, 2026
Why Did Nuvalent Stock Surge 15% Today?stocktwits.com
Via Stocktwits · November 17, 2025

Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.
Via The Motley Fool · March 13, 2026

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.
Via The Motley Fool · February 23, 2026

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Via The Motley Fool · February 19, 2026

Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.
Via The Motley Fool · February 19, 2026

This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.
Via The Motley Fool · February 19, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.
Via The Motley Fool · February 19, 2026

BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.
Via The Motley Fool · February 19, 2026
As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally stabilizing and corporate balance sheets bulging with record-breaking liquidity, the stage is set for a massive wave of
Via MarketMinute · December 30, 2025
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.
Via The Motley Fool · December 3, 2025
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.
Via The Motley Fool · December 3, 2025
One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.
Via The Motley Fool · December 3, 2025
Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?
Via The Motley Fool · December 3, 2025
Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Via The Motley Fool · November 19, 2025
Via Benzinga · November 17, 2025
Nuvalent reports durable neladalkib responses in pretreated and TKI-naïve ALK-positive NSCLC, with strong rates in the ALKOVE-1 trial.
Via Benzinga · November 17, 2025
Via Benzinga · November 17, 2025
Nuvalent said Monday almost a third of patients with a hard-to-treat form of lung cancer responded to its experimental drug.
Via Investor's Business Daily · November 17, 2025
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · November 14, 2025